US Pharma MarketingElicio’s KRAS cancer vaccine fails in Phase 2, shares plummet
Elicio Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals: What’s changing…
Elicio Therapeutics’ pancreatic cancer vaccine failed to improve outcomes in a mid-stage study, but the company is seeking funds to move ahead to a larger Phase 3 trial anyway.
Elicio reported ...
Source: Endpoints News